Compare Meta Platforms Inc (META) vs 10X Genomics Inc (TXG) Price & Performance

Meta Platforms (META) trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $719 and resistance at $726. Fundamentally, revenue grew to $200.97B in 2025 with a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a legal ruling on a youth addiction lawsuit in Massachusetts.

The outlook for META remains positive with strong analyst support—80% recommend Buy and a consensus price target of $781.00—driven by AI innovation and revenue growth. However, risks include regulatory challenges and high capital expenditures. Investors should weigh robust profitability against legal and competitive pressures in the social media and AI sectors.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.